7 Results
Subclinical Disease in Monkeys Exposed to H5N1 by Mouth and Stomach
Drinking raw milk contaminated with H5N1 virus can cause infection but may be less severe. Regardless, exposure by raw milk should be avoided.
Measuring Innovation: Laboratory Infrastructure to Deliver Essential HIV Clinical Trial Results
HIV clinical trials network laboratory functions will continue to evolve to align with scientific priorities and research approaches.
COVID-19 Respiratory Treatment Effective in Encephalitis Study
Antiviral drug molnupiravir, a COVID-19 treatment, was effective when tested in mice in preventing viruses that cause brain swelling, particularly in children. The scientists studied LACV because it broadly represents several RNA viruses that cause disease in the CNS, including Jamestown Canyon and Cache Valley viruses – which also were part of the study – and rabies, polio, West Nile, Nipah and several other viruses not part of the study.
Defining the Goals of HIV Science Through 2034
Discovery, Development and Delivery for an Increasingly Interconnected HIV Landscape
By Carl Dieffenbach, Ph.D., director, Division of AIDS, NIAID
We envision an HIV research enterprise that follows a logical evolution in addressing new scientific priorities informed by previous research progress. We will fund our next networks to align with updated research goals to take us through the end of 2034. Our capacity must reflect an increasing interdependence across clinical practice areas and public health contexts.
Scientists Identify Interferon-gamma as Potential SARS-CoV-2 Antiviral
Conditioning the lungs with interferon-gamma, a natural immune system protein best known for fighting bacterial infections, appears to be a strong antiviral for SARS-CoV-2, which causes COVID-19
The STOMP Trial Evaluates an Antiviral for Mpox
NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. In a video, Dr. Cyrus Javan of NIAID's Division of AIDS explains the importance of the STOMP trial.
Hepatitis B and C—A Closer Look at NIAID Research to Accelerate Elimination
Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of...
